Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Has Average Target Price of $20.50

Keros Therapeutics, Inc. (NASDAQ:KROS) has received a consensus rating of “Hold” from the nine analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $20.50.

Several research firms recently commented on KROS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Keros Therapeutics in a research note on Wednesday, August 12th. Zacks Research raised Keros Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 27th. Leerink Partners cut their price target on Keros Therapeutics from $30.00 to $23.00 and set an “outperform” rating on the stock in a report on Tuesday, August 4th. Wall Street Zen downgraded shares of Keros Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Saturday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price objective on shares of Keros Therapeutics in a research report on Tuesday, August 4th.

Keros Therapeutics Stock Up 0.4%

Shares of KROS opened at $11.33 on Friday. The firm’s fifty day simple moving average is $11.20 and its two-hundred day simple moving average is $12.32. Keros Therapeutics has a 12 month low of $9.69 and a 12 month high of $22.55.

Keros Therapeutics (NASDAQ:KROS) last posted its quarterly earnings data on Monday, August 3rd. The company reported ($1.45) earnings per share for the quarter, missing the consensus estimate of ($1.34) by ($0.11). Keros Therapeutics had a negative return on equity of 21.40% and a negative net margin of 256.60%. On average, equities research analysts predict that Keros Therapeutics will post -5.27 earnings per share for the current year.

Keros Therapeutics declared that its board has initiated a share buyback plan on Wednesday, September 9th that authorizes the company to buy back $5 million in outstanding shares. This buyback authorization authorizes the company to purchase up to 2.3% of its stock through open market purchases. Stock buyback plans are typically a sign that the company’s board of directors believes its stock is undervalued.

Insider Transactions at Keros Therapeutics

In other Keros Therapeutics news, insider Lorena Raquel Lerner sold 3,568 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $10.29, for a total value of $36,714.72. Following the completion of the sale, the insider directly owned 27,559 shares in the company, valued at approximately $283,582.11. This trade represents a 11.46% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 5,343 shares of company stock worth $54,985 over the last 90 days. 12.60% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Keros Therapeutics

Several institutional investors have recently made changes to their positions in KROS. Squarepoint Ops LLC bought a new stake in Keros Therapeutics in the 2nd quarter valued at about $334,000. Hsbc Holdings PLC raised its stake in Keros Therapeutics by 29.5% during the 2nd quarter. Hsbc Holdings PLC now owns 69,926 shares of the company’s stock worth $761,000 after buying an additional 15,940 shares during the period. Nantahala Capital Management LLC bought a new position in Keros Therapeutics in the second quarter worth approximately $15,091,483. Empowered Funds LLC bought a new position in Keros Therapeutics in the second quarter worth approximately $1,521,000. Finally, Public Employees Retirement System of Ohio acquired a new stake in Keros Therapeutics in the second quarter valued at approximately $538,000. Institutional investors and hedge funds own 71.56% of the company’s stock.

Keros Therapeutics Company Profile

Keros Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for diseases caused by dysfunctional signaling in the transforming growth factor-beta (TGF-β) superfamily of proteins. The company uses its research platform to design therapies intended to regulate signaling pathways involved in blood-cell production, bone health and cardiovascular function.

Keros’ investigational pipeline has included elritercept (KER-050), an activin receptor type IIA ligand trap being studied for hematologic conditions such as lower-risk myelodysplastic syndromes and myelofibrosis.